Identification and characterization of metabolites of ASP015K, a novel oral Janus kinase inhibitor, in rats, chimeric mice with humanized liver, and humans

References

• Bateman TJ, Reddy VG, Kakuni M, et al. (2014). Application of chimeric mice with humanized liver for study of human-specific drug metabolism. Drug Metab Dispos 42:1055–65
   PubMed Web of Science ®Google Scholar
• Dalvie D, Obach RS, Kang P, et al. (2009). Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357–68
   PubMed Web of Science ®Google Scholar
• De Serres M, Bowers G, Boyle G, et al. (2011). Evaluation of a chimeric (uPA+/+)/SCID mouse model with a humanized liver for prediction of human metabolism. Xenobiotica 41:464–75
   PubMed Web of Science ®Google Scholar
• FDA. (2008). Safety testing of drug metabolites. Rockville, MD: Food and Drug Administration
   Google Scholar
• Higashi Y, Inami M, Ito M, et al. (2012). ASP015K: a novel JAK inhibitor demonstrated potent efficacy in a chronic oxazolone-induced dermatitis model in rats. Abstracts (P093) of the 3rd World Psoriasis & Psoriatic Arthritis Conference (2012): “Psoriasis-a global health challenge”; Stockholm, Sweden
   Google Scholar
• Hop CE, Wang Z, Chen Q, Kwei G. (1998). Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901–3
   PubMed Web of Science ®Google Scholar
• Hussaini SH, Farrington EA. (2014). Idiosyncratic drug-induced liver injury: an update on the 2007 overview. Expert Opin Drug Saf 13:67–81
   PubMed Web of Science ®Google Scholar
• ICH. 2009. ICH Guideline M3 (R2): Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. International Conference on Harmonisation, Geneva, Switzerland
   Google Scholar
• Ihle JN. (1994). The Janus kinase family and signaling through members of the cytokine receptor superfamily. Proc Soc Exp Biol Med 206:268–72
   PubMed Web of Science ®Google Scholar
• Imada K, Leonard WJ. (2000). The Jak-STAT pathway. Mol Immunol 37:1–11
   PubMed Web of Science ®Google Scholar
• Inoue T, Sugihara K, Ohshita H, et al. (2009). Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver. Drug Metab Pharmacokinet 24:153–60
   PubMed Web of Science ®Google Scholar
• Johnston JA, Kawamura M, Kirken RA, et al. (1994). Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 370:151–3
   PubMed Web of Science ®Google Scholar
• Kalasz H, Petroianu G, Hosztafi S, et al. (2013). Medicinal chemistry of drugs with active metabolites following conjugation. Mini Rev Med Chem 13:1550–63
   PubMed Web of Science ®Google Scholar
• Kamimura H, Nakada N, Suzuki K, et al. (2010). Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab Pharmacokinet 25:223–35
   PubMed Web of Science ®Google Scholar
• Katoh M, Matsui T, Nakajima M, et al. (2004). Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 32:1402–10
   PubMed Web of Science ®Google Scholar
• Katoh M, Matsui T, Okumura H, et al. (2005). Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 33:1333–40
   PubMed Web of Science ®Google Scholar
• Klimas R, Mikus G. (2014). Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide. Br J Anaesth 113:935–44
   PubMed Web of Science ®Google Scholar
• Leonard WJ. (2001). Role of Jak kinases and STATs in cytokine signal transduction. Int J Hematol 73:271–7
   PubMed Web of Science ®Google Scholar
• Linnekin D, Mou S, Deberry CS, et al. (1997). Stem cell factor, the JAK-STAT pathway and signal transduction. Leuk Lymphoma 27:439–44
   PubMed Web of Science ®Google Scholar
• Oda K, Nakada N, Nagasaka Y. (2014). Sex differences in the metabolism of ASP015K, an novel oral Janus kinase (JAK) inhibitor, and its sulfuric metabolite M2 in rats. Xenobiotica (in press)
   Web of Science ®Google Scholar
• Papp K, Pariser D, Wierz G, et al. (2012). Phase IIa randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase (JAK) inhibitor, in patients with moderate to severe psoriasis. 3rd World Psoriasis & Psoriatic Arthritis Conference; 2012 Jun 27–Jul 1; Stockholm, Sweden
   Google Scholar
• Ram N, Kalasz H, Adeghate E, et al. (2012). Medicinal chemistry of drugs with active metabolites (N-, O-, and S-desalkylation and some specific oxidative alterations). Curr Med Chem 19:5683–704
   PubMed Web of Science ®Google Scholar
• Smith DA, Dalvie D. (2012). Why do metabolites circulate? Xenobiotica 42:107–26
   PubMed Web of Science ®Google Scholar
• Tateno C, Yoshizane Y, Saito N, et al. (2004). Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901–12
   PubMed Web of Science ®Google Scholar
• Testa B, Pedretti A, Vistoli G. (2012). Reactions and enzymes in the metabolism of drugs and other xenobiotics. Drug Discov Today 17:549–60
   PubMed Web of Science ®Google Scholar
• Wang Q, Jia R, Ye C, et al. (2005). Glucuronidation and sulfation of 7-hydroxycoumarin in liver matrices from human, dog, monkey, rat, and mouse. In Vitro Cell Dev Biol Anim 41:97–103
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Kuribayashi S, Inoue T, et al. (2010). Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry. Chem Res Toxicol 23:152–8
   PubMed Web of Science ®Google Scholar
• Zhu T. (2012). Pharmacodynamics of ASP015K, a novel Janus kinase inhibitor, in healthy volunteers. San Diego (CA): American College of Clinical Pharmacology
   Google Scholar